Targeted Tumor Mutation Testing
The GeneStrat® targeted test is a blood-based tumor profiling test that detects 6 of the most common mutations in non-small cell lung cancer. The test is covered independent of stage and can be used multiple times per patient to monitor changes in mutation status.
36-hour turnaround time
Extracts cfDNA and cRNA to detect fusions, indels, and point mutations
Download Sample Test Report
Download sample test report. Easily identify if tumor mutations were detected in cfDNA or cRNA on the two-page report.
Broad Tumor Mutation Testing
The GeneStrat NGS™ test is a blood-based, 52-gene panel composed of guideline recommended variants that helps identify patients with advanced stage NSCLC who may be eligible for targeted therapy or clinical trial enrollment.
Detects Single Nucleotide Variants (SNV), Insertion/deletions (Indels), Copy Number Variants (CNV), Fusion and Skipping variants
Supports multi-disciplinary collaboration
Download Sample Test Report
Identify actionable findings, including guideline recommended treatment options and active clinical trials in this concise, intuitive test report.
Host Immune Profile Testing
The VeriStrat® blood-based immune profiling test measures each patient’s immune response to lung cancer and helps inform physicians whether patients may have a more aggressive cancer. The VeriStrat® test may be utilized in both early and advanced stage NSCLC.
Download Sample Test Report
Download sample test report.Quickly identify a patient's VeriStrat status in this two-page report.
